Amoy Diagnostic Co. goes public on Shenzhen stock exchange, specialist in tumor analysis

The company has independent IP for nucleic acid molecular detection technology (ADx-ARMS ®) and is specialized in the detection of tumor-related genes such EGFR, KRAS, BRAF, EML4-ALK, PIK3CA, ROS1, NRAS, Her-2 and other.

China Bio news release, August 2, 2017

Amoy Diagnostic Co. goes public on Shenzhen stock exchange, specialist in tumor analysis
Scroll to top